Granules India Ltd.
NSE: GRANULESGranules India Ltd.: A 30-second snapshot
Granules India trades at ₹855.15, up 90.98% over the past 12 months and 16.54% over the past 3 months, sitting 5.83% below its 52-week high and above both its 50-DMA (₹820.82) and 200-DMA (₹663.56). Q1 FY27 news flow reports PAT up 60% YoY to ₹180 crore on 22% revenue growth, with one headline citing a debt-free position and peptide CDMO targets. Trailing PE is 31.96 against a forward PE of 21.68, and the stock ranks 2nd of 6 peers in the Pharma sector on both PE and quality score (54).
P/E
32.0
Forward P/E
21.7
ROE
—
Debt / Equity
29.73
Profit Margin
+11.8%
Div. Yield
+0.2%
5Y ROE > 15%
1/5
5Y FCF > 0
4/5
Quality
59/100
News
8 headlines · 7 positive · 0 negative
Granules India turns debt-free in Q1FY27, sets peptide CDMO targets - scanx.trade
scanx.trade
Granules India Ltd (BOM:532482) Q1 2027 Earnings Call Highlights: Record Revenue Growth and ... - finance.yahoo.com
finance.yahoo.com
Granules India Q1 FY27 net profit soars 60% to ₹180 cr on complex generics gain - pharma.economictimes.indiatimes.com
pharma.economictimes.indiatimes.com
Granules India records 60% YoY increase in Q1 PAT - business-standard.com
business-standard.com
Granules India Q1 Results: 22% revenue growth aids profit jump; Operating performance strong - CNBC TV18
CNBC TV18
Recent context
- ·Q1 FY27 (quarter ended June 2026) results reported PAT up 60% YoY to ₹180 crore on 22% revenue growth, described by finance.yahoo.com as 'record revenue growth' on July 21, 2026.
- ·A July 26, 2026 scanx.trade headline referenced Granules India turning 'debt-free' in Q1 FY27 and outlined 'peptide CDMO targets'.
- ·All 8 tracked news items in this window were rated positive or neutral by the sentiment classifier (7 positive, 1 neutral, 0 negative).
Strengths
- +5-year earnings growth of 53.4% and 5-year revenue growth of 22%, with free cash flow positive in 4 of the tracked years.
- +Q1 FY27 PAT grew 60% YoY to ₹180 crore on 22% revenue growth, reported consistently across multiple news sources on July 21, 2026.
- +News sentiment over the last 8 tracked items is 7 positive, 1 neutral, 0 negative, including a headline describing a debt-free Q1 FY27 position and peptide CDMO plans.
- +Ranks 2nd of 6 Pharma peers on both trailing PE (31.96) and quality score (54), and trades above both its 50-DMA and 200-DMA.
Weaknesses
- −ROE has exceeded 15% in only 1 of the tracked historical years, with a consistency score of 30/100 despite the 53.4% five-year earnings growth figure.
- −The historical persistence data classifies the debt trend as 'rising' (current debt-to-equity ~0.30x), a point worth reconciling against the recent news reference to a debt-free Q1 FY27 position.
- −Analyst rating data is unavailable (null) despite 8 analysts in coverage, limiting how sell-side consensus can be quantified from this dataset.
- −The 90.98% 12-month price gain and the stock's proximity to its 52-week high (5.83% below) have outrun the historical ROE-consistency record shown in the persistence metrics.
Open questions
- ?Does the multi-year persistence data (ROE above 15% in only 1 year, consistency score of 30/100) reflect a structural characteristic of the generics business, or a period the company has since moved past given the Q1 FY27 results?
- ?How does the 'debt-free' characterization in recent news reconcile with the 'rising' debt trend captured in the longer-run persistence metrics?
- ?With the stock up 90.98% over 12 months and close to its 52-week high, what does the gap between trailing PE (31.96) and forward PE (21.68) suggest about the earnings growth already priced in?
- ?How does Granules India's rank of 2nd of 6 Pharma peers on quality score and PE compare against dimensions not captured here, such as pipeline depth in complex generics and the peptide CDMO business?
Peer comparison: Pharma
Ranks 2 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| GRANULES | Granules India Ltd.You're viewing | 32.0 | — | 54 |
| Industry avg | across 5 peers | 47.9 | +14.9% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 38.6 | — | 57 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 65.0 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 70.5 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.1 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 30.3 | +8.8% | 4 |
Technical state
Current price
₹855.15
SMA 50
₹820.82
SMA 200
₹663.56
RSI (14)
54.0 (neutral)
From 52w high
-5.8%
1Y return
+91.0%
3M return
+16.5%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- mediumROE has exceeded 15% in only 1 of the historical years tracked and the consistency score stands at 30/100, despite 5-year earnings growth of 53.4% and 5-year revenue growth of 22% — earnings growth has not translated into a consistent return-on-equity track record.
- lowThe multi-year persistence data classifies the debt trend as 'rising', while current debt-to-equity is a moderate 0.30x (29.735 on the raw percent-scaled figure) — worth reconciling against recent news describing a debt-free Q1 FY27 position, since the persistence metric and the latest quarterly commentary describe different time windows.
- lowAnalyst rating is null in this data pull despite 8 analysts in coverage, so sell-side consensus cannot be quantified from the available fields this cycle.
- lowRSI of 53.96 is neutral, but the stock is up 90.98% over 12 months and 16.54% over 3 months while sitting only 5.83% below its 52-week high — a large price move already in place ahead of any observable indicator stress.
Cross-section contradictions
- News flow over the last 8 items is uniformly constructive (7 positive, 1 neutral, 0 negative), including a headline citing a debt-free Q1 FY27 position, while the longer-run persistence metric captured separately shows a 'rising' debt trend and a consistency score of 30/100 — the two data points span different time windows and have not yet reconciled in this dataset.
- The stock is up 90.98% over 12 months and trading only 5.83% below its 52-week high, while ROE has exceeded 15% in just 1 of the historical years tracked (consistency score 30/100) — the price move has run ahead of the historical profitability-consistency record shown in the persistence data.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 11 Aug 2026 · rotates through NIFTY 500 every ~5 days